Skip to main content

Advertisement

ADVERTISEMENT

Commentary

Ashley Headshot
Commentary
01/09/2024

Ashley McNairy, senior product director, Cotiviti

Ashley McNairy, senior product direct...
Even though many Medicare Advantage (MA) health plan executives braced for another year of declining performance on their Star Ratings, seeing their 2024 ratings drop for the second consecutive year has been a tough pill to swallow. Ashley...
Even though many Medicare Advantage (MA) health plan executives braced for another year of declining performance on their Star Ratings, seeing their 2024 ratings drop for the second consecutive year has been a tough pill to swallow. Ashley...
Even though many Medicare...
01/09/2024
First Report Managed Care

Advertisement

Sean Brady Headshot
Commentary
01/04/2024

Sean Brady, chief operating officer and co-founder, Ventric Health

Sean Brady, chief operating officer a...
The correlation between diabetes and heart failure poses a significant risk, as almost one-third of elderly individuals with diabetes encounter heart failure. Sean Brady provides insights into upcoming innovative solutions aimed at addressing...
The correlation between diabetes and heart failure poses a significant risk, as almost one-third of elderly individuals with diabetes encounter heart failure. Sean Brady provides insights into upcoming innovative solutions aimed at addressing...
The correlation between diabetes...
01/04/2024
First Report Managed Care
Anup Headshot
Commentary
12/21/2023

Anup Panthaloor, Firstsource executive vice president, Health Plans & Healthcare Services

Anup Panthaloor, Firstsource executiv...
The unwinding of Medicaid’s continuous enrollment and resulting redetermination activities were supposed to be nearly complete by spring 2024. According to Anup Panthaloor, Firstsource EVP, now, the initiative may be pushed into the summer of...
The unwinding of Medicaid’s continuous enrollment and resulting redetermination activities were supposed to be nearly complete by spring 2024. According to Anup Panthaloor, Firstsource EVP, now, the initiative may be pushed into the summer of...
The unwinding of Medicaid’s...
12/21/2023
First Report Managed Care
Commentary
12/20/2023
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
Clinicians should consider both the physical and psychological aspects of living with vitiligo and implement measures to identify and efficaciously address them, which can improve patient adherence, clinical outcomes, patient well-being, and...
Clinicians should consider both the physical and psychological aspects of living with vitiligo and implement measures to identify and efficaciously address them, which can improve patient adherence, clinical outcomes, patient well-being, and...
Clinicians should consider both...
12/20/2023
First Report Managed Care

Advertisement

Commentary
12/20/2023
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
In July 2023, GoodRx announced the launch of a new app known as Medicine Cabinet. In the press release, the company described the novel app as “a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine...
In July 2023, GoodRx announced the launch of a new app known as Medicine Cabinet. In the press release, the company described the novel app as “a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine...
In July 2023, GoodRx announced...
12/20/2023
First Report Managed Care
David Zawrotny Headshot
Commentary
12/19/2023

By David Zawrotny, Chief Service Officer at RetireeFirst

By David Zawrotny, Chief Service Offi...
David Zawrotny, Chief Service Officer at RetireeFirst, the premier Retiree Benefits Management provider, offers insights into enhancing the experience and outcomes for group plan sponsors and their retirees via industry-leading strategy,...
David Zawrotny, Chief Service Officer at RetireeFirst, the premier Retiree Benefits Management provider, offers insights into enhancing the experience and outcomes for group plan sponsors and their retirees via industry-leading strategy,...
David Zawrotny, Chief Service...
12/19/2023
First Report Managed Care
Commentary
12/14/2023
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus...
12/14/2023
First Report Managed Care

Advertisement

Commentary
12/14/2023
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
Prescription digital therapeutics (PDTs) allow patients and prescribers to work collaboratively and to use ongoing technological advances to diagnose, treat, and manage various conditions effectively. Unfortunately, it appears that a lack of...
Prescription digital therapeutics (PDTs) allow patients and prescribers to work collaboratively and to use ongoing technological advances to diagnose, treat, and manage various conditions effectively. Unfortunately, it appears that a lack of...
Prescription digital...
12/14/2023
First Report Managed Care
Commentary
11/28/2023
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
Prescription digital therapeutics offer the potential to improve adherence and clinical outcomes while decreasing direct and indirect costs, addressing gaps in care, and enabling patients to take an active role in their care.
Prescription digital therapeutics offer the potential to improve adherence and clinical outcomes while decreasing direct and indirect costs, addressing gaps in care, and enabling patients to take an active role in their care.
Prescription digital...
11/28/2023
First Report Managed Care
Commentary
11/20/2023
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
Since nonsegmental vitiligo is the most common type of vitiligo, the availability of the targeted therapy, Opzelura (topical ruxolitinib) cream, has the potential to help many patients living with vitiligo when appropriate. Improving access...
Since nonsegmental vitiligo is the most common type of vitiligo, the availability of the targeted therapy, Opzelura (topical ruxolitinib) cream, has the potential to help many patients living with vitiligo when appropriate. Improving access...
Since nonsegmental vitiligo is...
11/20/2023
First Report Managed Care

Advertisement

Advertisement